New hope for Hard-to-Treat thyroid cancer: lenvatinib shows promise

NCT ID NCT03573960

First seen Mar 11, 2026 · Last updated May 14, 2026 · Updated 7 times

Summary

This study looked at the safety of lenvatinib in 50 adults with advanced thyroid cancer that has spread and no longer responds to standard radioiodine therapy. Researchers tracked side effects and how often doses needed to be reduced. The goal was to see if lenvatinib can help control the disease in this tough-to-treat group.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THYROID NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • All India Institute of Medical Sciences

    New Delhi, National Capital Territory of Delhi, 110029, India

  • All India Institute of Medical Sciences

    Bhubaneswar, Odisha, 751019, India

  • BL Kapoor Hospital, New Delhi

    New Delhi, 110005, India

  • City Cancer Centre

    Vijayawada, 520002, India

  • Deenanath Mangeshkar Hospital

    Pune, Maharashtra, 411004, India

  • Indraprastha Apollo Hospital

    New Delhi, National Capital Territory of Delhi, 110076, India

  • Indrayani Hospital, Alandi

    Pune, 412105, India

  • Regional Cancer Centre, RCC, Thiruvananthapuram

    Thiruvananthapuram, Kerala, 695011, India

  • S. P. Medical College & A. G. Hospitals

    Bikaner, Rajasthan, 334003, India

  • Shetty's Hospital

    Bangalore, Karnataka, 560068, India

  • Tata Memorial Hospital

    Mumbai, 400012, India

Conditions

Explore the condition pages connected to this study.